Objective: In North America, the prevalence of nonmedical prescription opioid use (NMPOU), and morbidity and mortality related to prescription opioid analgesics (POAs) has risen sharply. Epidemiologic studies have suggested a high prevalence of mental health and pain comorbidities in NMPOU samples. Given the potential importance for interventions, a narrative review was conducted on studies reporting data on the co-occurrence of NMPOU with mental health problems and pain symptoms in general, treatment, or special populations.
P rescription opioid analgesics are important psychotropic medications for the treatment of severe and (or) chronic pain.1,2 POA consumption in North America is substantially higher than elsewhere in the world,3 amounting to 20 632 standard DDDs per million residents in Canada and 39 487 standard DDDs per million residents in the United States from 2007 to 2009. While POA consumption levels have doubled in both countries over the past decade alone, POA-related problems-for example, NMPOU, and morbidity and mortality rates-have substantially increased in parallel. For example, annual incidence of NMPOU in the United States approximately doubled from 6.5 million (2000) to 12.5 million (2007) , and 5.0% of the general US population reported NMPOU in the past year. 4, 5 While comparable and methodologically sound data are not available for the Canadian general population, several studies have documented high levels of NMPOU in student and street drug user populations. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Concurrently, substantial increases in POA-related morbidity and mortality have been observed. In the United States, POA-related emergency department admissions have increased 43% (from 172 726 to 247 669) between 2004 and 2006, 16 and POA-related admissions for substance use treatment have doubled in the United States and in Ontario in the past decade. 17, 18 Similarly, POA-related annual accidental poisoning deaths rose from 4000 (1999) to 13 800 (2006) in the United States, 19, 20 and doubled from 14 per million residents (1991) to 27 (2004) in Ontario, and currently contribute to a substantial proportion of drugrelated deaths. 21, 22 Recent data from both general and specific populations have suggested that mental health disorders and pain symptoms may be disproportionately prevalent in, and significantly distinguish people with NMPOU from, nonusers. Thus a substantial extent of NMPOU may occur in association with these comorbidity symptoms, and may either be a result of a lack of diagnosis or effective treatment, or a consequence of pharmacotherapeutic treatment itself. If validated, these insights would be of critical importance for consideration in NMPOU intervention development. On this basis, this paper presents a narrative review of study results on the co-occurrence of NMPOU and mental health problems and pain symptoms in North America.
Method
A literature search was conducted between December 2009 and June 2010 of databases MEDLINE, PubMed, PsycINFO, and Web of Science. We used the following search terms in combination and connected with 'and': prescription opioid, prescription opioid misuse, prescription opioid abuse, prescription opioid dependence, and analgesic, pain, mental*, psychopathology, comorbid*, psychia*, motives, self-med*, and population. Studies were included if they: provided data on prevalence of mental health problems and pain symptoms in NMPOU, and prevalence of NMPOU in people with mental health problems; or statistically analyzed the association between NMPOU and mental health and pain; or provided pain ratings for the NMPOU sample. All population groups were included (for example, general, street drug users, adolescents, and treatment populations). Seventy-four studies were found and fully reviewed vis-à-vis the study criteria, of which 35 were excluded and 39 were included in the review. Included studies were published between 1997 and 2009.
Results

NMPOU and Mental Health Problems
General Populations. Studies of large representative US samples have demonstrated strong associations of NMPOU and mental health problems, specifically depression and anxiety disorders. The ranges of odds ratios for the associations in the studies reviewed were 1.20 to 4.30 and 1.21 to 3.00, respectively (for details on the studies reviewed see online eTable 1).
The Martins et al 23 study of the NSDUH data found that extramedical opioid users were more likely to have had a major depressive episode than users of other drugs who did not use opioid analgesics. Extramedical oxycontin users were more likely to have had anxiety than users of other opioid analgesics (hydrocodone, oxycodone, and codeine). 23 Dowling et al 24 found that people with a mental or emotional problem were more likely to report recent onset of extramedical use of POAs, compared with people without. The Becker et al 25 analysis of the same data showed that panic and depressive symptoms were associated with NMPOU. Ghandour et al 26 found that pastyear extramedical opioid analgesic users who were possibly living with mental illness had higher odds of vindicating all symptoms of opioid dependence than those who were not. Similarly, using a subset of this data, Martins et al 27 showed that people with serious mental health problems were more likely to exhibit symptoms of opioid dependence than people without. A final study of this data found that women with a serious mental illness had greater odds for NMPOU than women without. 28 Similarly in adolescent samples, the Wu et al 34 analysis of the NSDUH found that people who abused POAs had increased odds of mental health service use, compared with people who did not abuse. Adolescents with POA dependence had increased odds of a depressive episode than those without. 34 The Edlund et al 35 39 US survey demonstrated that most users and misusers of oxycontin had experienced depression and anxiety, and to a smaller extent suicidal ideation and attempts. Green et al 40 found that women from substance abuse treatment centres who had abused POAs had increased odds of experiencing anxiety, and their male counterparts had increased odds of depression, both compared with people who had abused other drugs.
Abbreviations
In a sample of US adolescents with opioid use disorder from a substance abuse treatment program, Subramaniam and Stitzer 41 found that more people with NMPOU had attention-deficit hyperactivity disorder and experienced a manic episode, compared with heroin users.
Mental illness has also been shown to be prevalent in pain patients featuring NMPOU. Havens et al 42 found that the prevalence of lifetime depression was high in people with NMPOU and patients using POAs for pain. In a sample of chronic noncancer pain patients, Wasan et al 43 showed that patients with high psychiatric morbidity indicated a higher likelihood of misusing opioids and higher levels of current misuse, than those with low psychiatric morbidity. 43 Among US patients with chronic disabling occupational spinal disorder, Dersch et al 44 found that patients with opioid dependence were more likely to have an Axis I or II disorder (that is, major depressive, anxiety, antisocial personality, or borderline personality disorders) than people without.
Street Drug Users. Mental health problems were associated with NMPOU in street drug users. Fischer et al 12 found that mental health problems were prevalent in a cohort study of untreated illicit opioid users from 5 Canadian cities (OPICAN study), and nearly one-half met criteria for depression. Latent class analysis of the cohort found that respondents involving NMPOU had the highest proportion of people with depression, compared with users of other drugs. 45 The Havens et al 46 Pain Ratings. Most of the studies of pain ratings indicated a positive relation between pain levels and NMPOU. Miller et al 53 found that the average pain rating among admissions to a US addictions treatment centre was moderate for POA-dependent inpatients. In a similar setting, patients' average pain ratings were moderate and most with chronic pain indicated that their addiction worsened when pain increased. 55 The Ives et al 47 study of pain patients found that POA misusers had a baseline pain score that was higher than nonmisusers. Havens et al 42 found that the pain severity of people reporting NMPOU was high but lower than pain patients' pain. The Jamison et al 56 study of pain management patients in the United States found that aberrant medication-related behaviours were positively associated with pain ratings. In a US study of people with chronic disabling occupational spinal disorder, those with opioid dependence disorder had higher pain intensity than people without. 44 In contrast, a study of US chronic pain patients found that POA abusers had similar average pain ratings, compared with nonabusers. 57 Negative Findings. A small number of studies did not associate pain and NMPOU. In the Ives et al 47 
Discussion
Most studies reviewed demonstrated that NMPOU is strongly associated with mental health problems (particularly mood, anxiety, and personality disorders) and pain symptoms in various populations. Considering the substantial increases in the prevalence of NMPOU and related morbidity and mortality outcomes in North America, these finding have key implications.
As most studies were cross-sectional, mental illness or pain may have led to NMPOU, or vice versa, or NMPOU and the comorbidities observed may have common factors, including neurobiological underpinnings that increase the person's susceptibility to both. 32, 59, 60 Multiple etiologies likely account for the comorbidities, and further research is required to elucidate the role of different causal directionalities.
The strong association between NMPOU and the observed comorbidities should not be surprising. Given POAs' primary medical function as pain analgesics, many people with pain comorbidities may have been first exposed to POAs in the context of pain care, and may have become habituated to POA use or continued their use after the termination of medical care for pain symptoms that may have persisted or re-occurred. 35, 38 Similarly, the broad analgesic effects of POAs may bring desirable benefits or relief for people with mental health problems not adequately diagnosed or treated by other medical interventions. As such, NMPOU in many people with pain or mental health comorbidities may reflect a form of self-medication that has been observed for other populations of licit and illicit psychoactive substance users (for example, alcohol, marijuana, or tobacco) in which comorbidities are highly prevalent. [61] [62] [63] Within the body of studies reviewed, there is limited-and conflicting-direct evidence for possible self-medication dynamics among nonmedical POA users with either mental health or pain problems. Specifically, Edlund et al 35 found mental health problem-but not pain-symptoms in 2002 to predict NMPOU in subsequent assessments of their study sample. Ives et al 47 found neither depression nor pain symptoms to predict NMPOU at the 1-year follow-up of their sample of chronic pain patients. More and better longitudinal data are clearly needed to determine possible causality, yet the potentially important issue and role of self-medication for NMPOU is neglected and understudied on several fronts. As recent commentaries have also pointed out, surveys and studies focusing on NMPOU need to include an assessment of the motives for NMPOU to better determine the causes and driving factors behind such use, which are also essential to formulate and devise appropriate interventions. 64, 65 A further contextual factor is that POAs in North America are far more widely used and available than anywhere in the world, and hence more easily available and accessible for NMPOU. In Canada, total annual POA use increased from 10 209 standard DDD in the period from 2001 to 2003, to 20 632 standard DDD from 2007 to 2009, that is, doubled over the present decade. 3 These levels, in comparison on a per capita basis, are 3 times the level of POA use in the United Kingdom, and more than double the level in Australia. 3 Moreover, several studies have documented that the (changing) levels of POA available in the population are strongly associated with (changing) levels of POA-related morbidity (for example, emergency department or substance use treatment admissions) and mortality (for example, overdose deaths). 66, 67 While current national estimates of NMPOU for the Canadian general adult population are problematic, Ontario-based estimates suggest that this prevalence may be as high as 6.5%; this value would translate into more than 1.5 million Canadians aged 16 years and older. 6, 68 Further, surveys have shown that most people with NMPOU obtain their POAs by diversion or nonmedical sourcing from family or friends. 69 In this wider context, people with need or desire for NMPOU are unlikely to face too many barriers to find or gain access to POAs for such purposes.
However, these contextual factors ought not to be interpreted causally, as the results of our review clearly suggest that people with mental health or pain comorbidities are substantially more likely to engage in NMPOU than people without. While these dynamics clearly raise fundamental conceptual questions for the dichotomous constructs of medical, compared with nonmedical use of POAs, the crucial implications for both prevention and treatment interventions for NMPOU are that these ought to actively consider and address possible pain or mental health comorbidity problems. 65 Conversely, any medical treatment involving POAs for pain care prior to initiation should examine patients for pre-existing mental health problems or conditions, and facilitate appropriate care.
As other fields of substance use have demonstrated, translating adequate and effective comorbidity care into good practice is complex and difficult, partly because it requires active cooperation of different disciplines and sets of medical expertise. 70, 71 Simultaneously, the presence or risk of comorbidities in patients requiring POAs for pain must not work as a barrier to adequate pain care.
In the current policy and practice environment-where POA-related harms including NMPOU and POA-related morbidity or mortality are increasingly recognized as highly problematic-it would be convenient or opportunistic to suggest that potentially risky or difficult patients (for example, people with mental health problems, drug dependence, or other comorbidities) are excluded from pain or other medical care involving POAs. However, this would not constitute good medical practice for individual patients, nor would it be desirable for public health, as it is clearly evident that pain prevalence and need for adequate pain care are disproportionately prevalent in high-risk populations (for example, people with comorbidities). 64, [72] [73] [74] Similarly, the high prevalence of mental health problems among people engaging in NMPOU may either point to the potentially severe effects of pain problems on mental health, or the current mental health care system's inability to comprehensively or effectively diagnose or treat people with mental health problems. These are the gaps where causal solutions and remedies ought to be applied that can eventually be expected to translate into a reduction of need for NMPOU among people with pain or mental health comorbidities.
Conclusion
The strong associations between NMPOU and mental health and pain comorbidities have been observed predominantly in North America-the world's region with the highest and steeply rising POA consumption. 75 The vast abundance and easy availability of POAs from both medical and nonmedical sources, 76, 77 combined with their powerful and broad analgesic effects, have made POAs a popular and omnipresent pharmacotherapeutic tool to deal with common yet complex ills in the population. 6 The rising problem of NMPOU can only be effectively addressed if the strongly associated comorbidity phenomena of mental health and pain problems are more effectively identified, prevented, and treated.
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